DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Park JW, Finn RS, Kim JS , et al.
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Clin Cancer Res 2011;
17 (7) 1973-1983
We do not assume any responsibility for the contents of the web pages of other providers.